In agreement with this possibility, Sweetser et al60 attributed the lack of efficacy of the CRF1r antagonist to improve colonic symptoms in patients with IBS to an impairment of the integrated CRF1r‐CRF2r response. This evidence concerns the gene CRHR2 and irritable bowel syndrome.